High Survivin Levels Predict Poor Clinical Response to Infliximab Treatment in Patients with Rheumatoid Arthritis

Seminars in Arthritis and Rheumatism

Volumn 41, Issue 5, 2012, Pages 652-657

  Isgren, Anniella ^a   Forslind, Kristina ^b   Erlandsson, Malin ^a   Axelsson, Carl ^a   Andersson, Sofia ^a   Lund, Anneli ^a   Bokarewa, Maria ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Infliximab; Rheumatoid arthritis; Surviving; Treatment

Indexed keywords

AZATHIOPRINE; CHLORAMBUCIL; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; SURVIVIN;

ADULT; AGED; ARTICLE; BONE RADIOGRAPHY; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ARTHROGRAPHY; FEMALE; HEALTH STATUS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; JOINTS; MALE; MIDDLE AGED; PATIENT SELECTION; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84859434524     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2011.08.005     Document Type: Article

References (19)

1. Chen Y.F., Jobanputra P., Barton P., Jowett S., Bryan S., Clark W., et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006, 10:1-229.
2. Kievit W., Adang E.M., Fransen J., Kuper H.H., van de Laar M.A., Jansen T.L., et al. The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Ann Rheum Dis 2008, 67:1229-1234.
3. Hyrich K.L., Deighton C., Watson K.D., Symmons D.P., Lunt M. Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity. Rheumatology (Oxford) 2009, 48:1323-1327. BSRBR Control Centre Consortium, British Society for Rheumatology Biologics RegisterBritish Society for Rheumatology Biologics Register.
4. Olofsson T., Englund M., Saxne T., Jöud A., Jacobsson L.T., Geborek P., et al. Decrease in sick leave among patients with rheumatoid arthritis in the first 12 months after start of treatment with tumour necrosis factor antagonists: a population-based controlled cohort study. Ann Rheum Dis 2010, 69:2131-2136.
5. Kievit W., Fransen J., Oerlemans A.J., Kuper H.H., van der Laar M.A., de Rooij D.J., et al. The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. Ann Rheum Dis 2007, 66:1473-1478.
6. Strand V., Kimberly R., Isaacs J.D. Biologic therapies in rheumatology: lessons learned, future directions. Nat Rev Drug Discov 2007, 6:75-92.
7. Hyrich K.L., Watson K.D., Silman A.J., Symmons D.P. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2006, 45:1558-1565. British Society for Rheumatology Biologics Register.
8. Julià A., Erra A., Palacio C., Tomas C., Sans X., Barceló P., Marsal S. An eight-gene blood expression profile predicts the response to infliximab in rheumatoid arthritis. PloS One 2009, 4:e7556.
9. van Baarsen L.G., Wijbrandts C.A., Gerlag D.M., Rustenburg F., van der Pouw Kraan T.C., Dijkmans B.A., et al. Pharmacogenomics of infliximab treatment using peripheral blood cells of patients with rheumatoid arthritis. Genes Immun 2010, 11:622-629.
10. Hueber W., Tomooka B.H., Batliwalla F., Li W., Monach P.A., Tibshirani R.J., et al. Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis. Arthritis Res Ther 2009, 11:R76.
11. Klaasen R., Thurlings R.M., Wijbrandts C.A., van Kuijk A.W., Baeten D., Gerlag D.M., et al. The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study. Arthritis Rheum 2009, 60:3217-3224.
12. Bokarewa M., Lindblad S., Bokarew D., Tarkowski A. Balance between survivin, a key member of the apoptosis inhibitor family, and its specific antibodies determines erosivity in rheumatoid arthritis. Arthritis Res Ther 2005, 7:R349-R358.
13. Altieri D.C. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003, 22(53):8581-8589.
14. Duffy M.J., O'Donovan N., Brennan D.J., Gallagher W.M., Ryan B.M. Survivin: a promising tumor biomarker. Cancer Lett 2007, 249(1):49-60.
15. Svensson B., Hafström I., Forslind K., Albertsson K., Tarkowski A., Bokarewa M.I. Increased expression of proto-oncogene survivin predicts joint destruction and persistent disease activity in early rheumatoid arthritis. Ann Med 2010, 42:45-54.
16. Nishimura K., Sugiyama D., Kogata Y., Tsuji G., Nakazawa T., Kawano S., et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007, 146:797-808.
17. Prevoo M.L., van 't Hof M.A., Kuper H.H., van Leeuwen M.A., van de Putte L.B., van Riel P.L. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:44-48.
18. van Gestel A.M., Prevoo M.L., van 't Hof M.A., van Rijswijk M.H., van de Putte L.B., van Riel P.L. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996, 39:34-40.
19. van der Heijde D.M., van Leeuwen M.A., van Riel P.L., Koster A.M., van 't Hof M.A., van Rijswijk M.H., et al. Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum 1992, 35:26-34.